Rapid Acting Insulin Market Growth, Size, Trends, Demand, Revenue, Share and Future Scope
Global Rapid Acting Insulin Market Size- By Product, By Indication, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
| Published: Nov-2022 | Report ID: PHAR2210 | Pages: 1 - 243 | Formats*: |
| Category : Pharmaceutical | |||
Rapid Acting Insulin Market Introduction and Overview
According to SPER Market Research, the Global Rapid Acting Insulin Market is estimated to reach USD 11.85 billion by 2032 with a CAGR of 4.90%.
The report includes an in-depth analysis of the global Rapid Acting Insulin market, including market size and trends, Procedure mix, distribution channels, and supplier analysis.Rapid-acting insulin is a type of insulin that acts quickly after injection to lower blood sugar levels. It is used to manage post-meal glucose spikes in individuals with diabetes.
- Increasing prevalence of diabetes: The rising global incidence of diabetes, particularly type 1 and type 2 diabetes, is driving the demand for rapid-acting insulin as an essential treatment option.
- Technological advancements: Continuous advancements in insulin delivery systems, such as insulin pens and pumps, are improving the convenience and accuracy of insulin administration, thereby boosting the market growth.
Market Opportunities and Challenges
The global rapid-acting insulin market is driven by several factors. Firstly, the increasing prevalence of diabetes, including both type 1 and type 2 diabetes, is fuelling the demand for rapid-acting insulin as a vital treatment option. Secondly, continuous technological advancements in insulin delivery systems, such as pens and pumps, are enhancing the convenience and accuracy of insulin administration, thereby promoting market growth. Thirdly, growing awareness about diabetes management, coupled with higher healthcare expenditure, is contributing to the expansion of the market. Lastly, the aging population, which is more susceptible to diabetes, is driving the demand for rapid-acting insulin, and as the global population ages, the market is expected to further expand.
However, the global rapid-acting insulin market encounters challenges such as competition from alternative therapies, including oral antidiabetic medications and non-insulin injectables. Affordability concerns due to the high cost of insulin, regulatory barriers, and stringent approval processes also hinder market growth. Additionally, ensuring patient adherence to therapy and providing adequate education on insulin administration techniques and blood glucose monitoring pose critical challenges. Overcoming these obstacles requires addressing cost concerns, streamlining regulatory processes, and improving patient education to foster the growth of the market.
Market Competitive Landscape
The global Rapid Acting Insulin is characterized by high competition, with multiple players operating in the industry. The key players in the global Rapid Acting Insulin market include Biocon Limited, Eli Lilly, Sanofi S.A., Geropharm, Wockhardt Ltd., Novo Nordisk A/S, ManKind Corporation, Adocia, Gan & Lee Pharmaceuticals Co. Ltd., Merck & Co. Inc. and Others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Product, By Indication, By Distribution Channel |
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe |
| Companies Covered | Biocon Limited, Eli Lilly, Sanofi S.A., Geropharm, Wockhardt Ltd., Novo Nordisk A/S, ManKind Corporation, Adocia, Gan & Lee Pharmaceuticals Co. Ltd., Merck & Co. Inc. and Others. |
COVID-19 Impact on Global Rapid Acting Insulin Market
The global rapid-acting insulin market has been significantly impacted by the COVID-19 pandemic. Disruptions in the supply chain have caused challenges in insulin production and distribution. Changes in healthcare utilization, with a focus on COVID-19 management, have resulted in decreased diabetes diagnoses and potentially reduced demand for rapid-acting insulin. Financial constraints and shifting healthcare priorities have also affected affordability and investment in the market. These effects highlight the need to address supply chain issues, ensure timely diabetes diagnosis, tackle affordability concerns, and regain focus on research and development in the post-pandemic recovery.
Key Target Audience:
- Clinics and Hospitals
- Diabetes Clinicians and Specialists
- Diagnostic Laboratories
- Government Health Departments
- Pharmacy Chains and Retailers
- Research Institutes and Academic Institutions
- Self-care Individuals with Diabetes
- Wholesale Distributors and Suppliers
- Others
Our in-depth analysis of the Rapid Acting Insulin Market includes the following segments:
| By Indication: |
|
| By Distribution Channel: |
|
Key Topics Covered in the Report:
- Global Rapid Acting Insulin Market Size (FY’2022-FY’2032)
- Overview of Global Rapid Acting Insulin Market
- Segmentation of Global Rapid Acting Insulin Market By Product (Lispro Insulin, Aspart Insulin, Glulisine Insulin)
- Segmentation of Global Rapid Acting Insulin Market By Indication (Type 1 Diabetes and Type 2 Diabetes)
- Segmentation of Global Rapid Acting Insulin Market By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Stores)
- Statistical Snap of Global Rapid Acting Insulin Market
- Expansion Analysis of Global Rapid Acting Insulin Market
- Problems and Obstacles in Global Rapid Acting Insulin Market
- Competitive Landscape in the Global Rapid Acting Insulin Market
- Impact of COVID-19 and Demonetization on Global Rapid Acting Insulin Market
- Details on Current Investment in Global Rapid Acting Insulin Market
- Competitive Analysis of Global Rapid Acting Insulin Market
- Prominent Players in the Global Rapid Acting Insulin Market
- SWOT Analysis of Global Rapid Acting Insulin Market
- Global Rapid Acting Insulin Market Future Outlook and Projections (FY’2022-FY’2032)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data2.1.2 Primary data2.1.3 SPER’s internal database2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers4.1.2 Restraints4.1.3 Opportunities4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Rapid Acting Insulin Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths5.1.2 Weaknesses5.1.3 Opportunities5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape5.2.2 Economic landscape5.2.3 Social landscape5.2.4 Technological landscape5.2.5 Environmental landscape5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers5.3.2 Bargaining power of Buyers5.3.3 Threat of Substitute5.3.4 Threat of new entrant5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Global Rapid Acting Insulin Market, By Product, 2019-2032 (USD Million)
6.1 Lispro Insulin6.2 Aspart Insulin6.3 Glulisine Insulin
7. Global Rapid Acting Insulin Market, By Indication, 2019-2032 (USD Million)
7.1 Type 1 Diabetes7.2 Type 2 Diabetes
8. Global Rapid Acting Insulin Market, By Distribution Channel, 2019-2032 (USD Million)
8.1 Hospital Pharmacies8.2 Drug Stores and Retail Pharmacies8.3 Online Stores
9. Global Rapid Acting Insulin Market, By Region, 2019-2032 (USD Million)
9.1 North America
9.1.1 United States9.1.2 Canada9.1.3 Mexico
9.2 Europe
9.2.1 Germany9.2.2 United Kingdom9.2.3 France9.2.4 Italy9.2.5 Spain9.2.6 Rest of Europe
9.3 Asia-Pacific
9.3.1 China9.3.2 Japan9.3.3 India9.3.4 Australia9.3.5 South Korea9.3.6 Rest of Asia-Pacific
9.4 South America
9.4.1 Brazil9.4.2 Argentina9.4.3 Rest of South America
9.5 Middle East & Africa
9.5.1 Kingdom of Saudi Arabia9.5.2 United Arab Emirates9.5.3 Rest of Middle East & Africa
10. Company Profiles
10.1 Adocia
10.1.1 Company details10.1.2 Financial outlook10.1.3 Product summary10.1.4 Recent developments
10.2 Biocon Limited
10.2.1 Company details10.2.2 Financial outlook10.2.3 Product summary10.2.4 Recent developments
10.3 Eli Lilly
10.3.1 Company details10.3.2 Financial outlook10.3.3 Product summary10.3.4 Recent developments
10.4 Gan & Lee Pharmaceuticals Co. Ltd.
10.4.1 Company details10.4.2 Financial outlook10.4.3 Product summary10.4.4 Recent developments
10.5 Geropharm
10.5.1 Company details10.5.2 Financial outlook10.5.3 Product summary10.5.4 Recent developments
10.6 MannKind Corporation
10.6.1 Company details10.6.2 Financial outlook10.6.3 Product summary10.6.4 Recent developments
10.7 Merck & Co. Inc.
10.7.1 Company details10.7.2 Financial outlook10.7.3 Product summary10.7.4 Recent developments
10.8 Novo Nordisk A/S
10.8.1 Company details10.8.2 Financial outlook10.8.3 Product summary10.8.4 Recent developments
10.9 Sanofi S.A.
10.9.1 Company details10.9.2 Financial outlook10.9.3 Product summary10.9.4 Recent developments
10.10 Wockhardt Ltd.
10.10.1 Company details10.10.2 Financial outlook10.10.3 Product summary10.10.4 Recent developments
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
The Rapid Acting Insulin Market is projected to reach USD 11.85 billion by 2032, growing at a CAGR of 4.9% during the forecast period.
The Rapid Acting Insulin Market grew in market size from 2022. The Market is expected to reach USD 11.85 billion by 2032, at a CAGR of 4.9% during the forecast period.
The Rapid Acting Insulin Market CAGR of 4.9% during the forecast period.
You can get the sample pages by clicking the link - Click Here
The Rapid Acting Insulin Market size is USD 11.85 billion from 2022 to 2032.
The Rapid Acting Insulin Market segment is Covered By Product, By Indication, By Distribution Channel.
The North America region is anticipated to have the highest market share in the Rapid Acting Insulin Market.
The key players in the market include Companies Covered Adocia, Biocon Limited, Eli Lilly, Gan & Lee Pharmaceuticals Co. Ltd., Geropharm, MannKind Corporation, Merck & Co. Inc., Novo Nordisk A/S, Sanofi S.A., Wockhardt Ltd.
The rise in the global prevalence of diabetes is driving the global market for rapid acting insulin.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
